Ameliorating effect of emodin, a constitute of Polygonatum multiflorum, on cycloheximide-induced impairment of memory consolidation in rats.
The aim of the present study was intended to investigate the ameliorating effects of emodin on memory consolidation via cholinergic, serotonergic and GABAergic neuronal systems in rats. First, we evaluated the ameliorating effects of emodin on cycloheximide (CXM)-induced impairment of passive avoidance response in rats. Secondly, we clarified the role of cholinergic, serotonergic or GABAergic system on the ameliorating effect of emodin by using 5-HT1A receptor partial agonist, 5-HT2 receptor antagonist, GABAB agonist, GABAA antagonist and muscarinic receptor antagonist. Emodin protected the rat from CXM-induced memory consolidation impairment. The beneficial effect of emodin on CXM-induced memory consolidation impairment was amplified by 8-OH-DPAT (5-HT1A receptor partial agonist) and ritanserin (5-HT2 receptor antagonist), but reduced by scopolamine. These results suggested that the beneficial effect of emodin on CXM-induced memory consolidation impairment was amplified by serotonergic 5-HT1A-receptor partial agonist and 5-HT2 receptor antagonist but reduced by muscarinic receptor antagonist.
Lu
Ming-Chin
MC
Post-Baccalaureate School of Chinese Medicine, China Medical University, Taichung, Taiwan, ROC.
Hsieh
Ming-Tsuen
MT
Wu
Chi-Rei
CR
Cheng
Hao-Yuan
HY
Hsieh
Chia-Chang
CC
Lin
Yao-Tung
YT
Peng
Wen-Huang
WH
D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000008:administration & dosage / Q000494:pharmacology; D000284:Administration, Oral; D000818:Animals; D001418:Baclofen / Q000008:administration & dosage / Q000494:pharmacology; D001640:Bicuculline / Q000008:administration & dosage / Q000494:pharmacology; D003513:Cycloheximide / Q000008:administration & dosage / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004642:Emodin / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D018755:GABA Agonists / Q000008:administration & dosage / Q000494:pharmacology; D018756:GABA Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D007279:Injections, Subcutaneous; D007858:Learning / Q000187:drug effects; D008297:Male; D008568:Memory / Q000187:drug effects*; D008569:Memory Disorders / Q000139:chemically induced / Q000517:prevention & control*; D018517:Plant Roots / Q000737:chemistry; D031384:Polygonatum / Q000737:chemistry*; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D016713:Ritanserin / Q000008:administration & dosage / Q000494:pharmacology; D012601:Scopolamine / Q000008:administration & dosage / Q000494:pharmacology; D058825:Serotonin 5-HT1 Receptor Agonists; D058830:Serotonin 5-HT2 Receptor Antagonists
D018755:GABA Agonists; D018756:GABA Antagonists; D011500:Protein Synthesis Inhibitors; D058825:Serotonin 5-HT1 Receptor Agonists; D058830:Serotonin 5-HT2 Receptor Antagonists; D016713:Ritanserin; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D003513:Cycloheximide; D012601:Scopolamine; D001418:Baclofen; D004642:Emodin; D001640:Bicuculline